Jack Carter

机构：Prelude Therapeutics Incorporated (United States) · ORCID：0000-0002-7784-7897

发表论文 79 篇 · 总被引 252 次 · h-index 7

代表论文

• PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers (2025 · Cancer Research · 被引 20)
• PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands (2025 · Journal of Experimental & Clinical Cancer Research · 被引 13)
• Identification of triazolyl KAT6 inhibitors via a templated fragment approach (2024 · Bioorganic & Medicinal Chemistry Letters · 被引 6)
• Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers (2023 · Molecular Cancer Therapeutics · 被引 4)
• Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2 (2024 · Cancer Research · 被引 3)
• Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models (2025 · Cancer Research · 被引 1)